Mark E. Bunnage insider trades: Vertex Pharmaceuticals Inc / Ma (VRTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | VRTX | ↓ Sell | 33 | $453.45 | $15K | Direct | May 19, 2026 (4d) |
| Feb 25, 2026 | VRTX | ↓ Sell | 620 | $486.35 | $302K | Direct | Feb 26, 2026 (1d) |
| Feb 18, 2026 | VRTX | ↓ Sell | 3,619 | $484.31 | $1.8M | Direct | Feb 19, 2026 (1d) |
| Feb 11, 2026 | VRTX | ↓ Sell | 2,021 | $460.43 | $931K | Direct | Feb 12, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VRTX insiders
Open-market trades in the last 12 months
About Mark E. Bunnage's insider trades
Mark E. Bunnage is EVP, Chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX). Since Feb 11, 2026, Mark has reported no open-market purchases and 4 sales worth $3.0M on SEC Form 4. In the last 12 months: 4 sales ($3.0M).
Their filings also include shares withheld for taxes (4 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VRTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.